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During hunger, a series of high-amplitude contractions of the stomach and small intestine (phase 
III), which form part of a cycle of quiescence and contractions (known as the migrating motor 
complex, MMC), play a “housekeeping” role prior to the next meal, and may contribute toward 
the development of hunger. Several gastrointestinal (GI) hormones are associated with phase 
III MMC activity, but currently the most prominent is motilin, thought to at least partly mediate 
phase III contractions of the gastric MMC. Additional GI endocrine and neuronal systems play 
even more powerful roles in the development of hunger. In particular, the ghrelin-precursor 
gene is proving to have a complex physiology, giving rise to three different products: ghrelin 
itself, which is formed from a post-translational modification of des-acyl-ghrelin, and obestatin. 
The receptors acted on by des-acyl-ghrelin and by obestatin are currently unknown but both 
these peptides seem able to exert actions which oppose that of ghrelin, either indirectly or 
directly. An increased understanding of the actions of these peptides is helping to unravel a 
number of different eating disorders and providing opportunities for the discovery of new drugs 
to regulate dysfunctional gastric behaviors and appetite. To date, ghrelin and motilin receptor 
agonists and antagonists have been described. The most advanced are compounds which 
activate the ghrelin and motilin receptors which are being progressed for disorders associated 
with gastric hypomotility.
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illustrates the peak strength of the contractions which can begin 
in the middle part of the stomach and are temporally associ-
ated with hunger sensations. In addition, other GI endocrine 
and neuronal systems play even more powerful roles in the 
development of hunger.
The ways in which appetite can be modulated via mechanisms 
originating within the brain, have previously been described 
(Rolls, 1981; Cline et al., 2009). Here we focus on the role of 
the upper GI tract (and its large compliment of hormones) in 
the mechanisms of hunger, dividing the discussion into four 
key areas:
•   The movements of the stomach and small intestine during 
hunger and their relationships with the release of GI hormo-
nes which are primarily involved in regulating GI motility, and 
which also assist in the development of hunger.
•   The release of other GI hormones from the stomach during 
hunger,  which  although  having  the  potential  to  affect 
gastric motility, appear to play greater roles in driving hun-
ger and appetite, operating via GI, vagal, and central nerve 
mechanisms.
•   The dysregulation of these processes during illness.
•   The ways in which an understanding of the hungry stomach is 
leading to the discovery of new drugs to regulate dysfunctional 
gastric behaviors and appetite.
IntroductIon
Read (1992) defined “hunger” as a word usually applied to the 
sensation of needing food, whereas in humans at least, the word 
“appetite” also encompasses the desire to eat and the enjoyment of 
certain foods. Hunger is not abolished by distension of the stom-
ach by a balloon or by infusion of lipids into the bloodstream, but 
by a nutrient load within the small intestine (Read, 1992). This 
suggested that mechanisms within the gastrointestinal (GI) tract 
have the capacity to influence what we eat. A subsequent explosion 
in understanding how neuronal and hormonal communication 
from different regions of the GI tract can modulate food intake 
(Bray, 2000) and energy homeostasis (Murphy and Bloom, 2006) 
now places the gut, the largest endocrine organ of the body, at the 
center of an integrated gut–brain–energy axis, in which digestion is 
coordinated with appetite, satiation, and metabolism. It follows that 
disruption of this axis can be linked to early or late satiety, nausea, 
and to several conditions associated with eating and metabolic 
disorders and/or delayed gastric emptying.
During hunger, the muscle of the stomach and small intestine 
is largely quiescent. However, a regular cycle of contractions 
play a “housekeeping” role prior to the next meal and may 
contribute toward the development of hunger. This cycle of 
quiescence and contractions is known as the migrating motor 
complex (MMC), and particular phases of the MMC are closely 
associated with the release of certain GI hormones. Figure 1 Frontiers in Pharmacology  | Gastrointestinal Pharmacology    February 2011  | Volume 1  | Article 145  |  2
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the mechanisms of phase III MMC activity in the human and dog 
stomach (see Mechanisms of the MMC, below) and the absence 
of a functional motilin system in rats and mice (He et al., 2010) 
indicates that the mechanisms of gastric MMCs in these rodents 
are very different to those in humans and dogs. Perhaps in rats and 
mice the functions of motilin are unnecessary or are mimicked 
by those of ghrelin (Argia et al., 2007). Whatever the explanation, 
the differences indicate that in terms of human GI functions, the 
translational value of studies on MMC activity in rodents must be 
treated with caution. For this reason, this section focuses only on 
studies which use humans or dogs.
FunctIons oF the MMc
Phase III MMC activity is thought to help prevent bacterial over-
growth in the upper gut and clear the stomach and intestine from 
any undigested material not removed during normal gastric empty-
ing (Vantrappen et al., 1977; Nieuwenhuijs et al., 1998; Husebye, 
1999). MMCs may also help create the sensation of hunger. Itoh 
et al. (1975) first described phase III MMC contractions as “hunger 
contractions.” More recently phase III activity of MMCs which 
spontaneously originate in the stomach were shown to corre-
late with the sensation of hunger – a similar correlation was not 
observed for MMCs originating within the small intestine (Ang 
et al., 2008a,b). Thus, hunger sensations seem to primarily emanate 
from the gastric antrum.
MechanIsMs oF the MMc
Although phases II and III are mediated via the enteric nervous 
system (ENS), phase III is initiated via the vagus nerve. Thus in 
the canine stomach, phase III MMC activity has been prevented 
or reduced by vagotomy or other procedures which reduce vagal 
activity (Hall et al., 1984; Tanaka et al., 2001; Shibata et al., 2002). 
However, the mechanisms which regulate the periodicity of the 
MMC cycle are regionally specific and are thought to be governed 
by the local release of 5-HT and motilin from the mucosa of the 
upper gut.
Nakajima et al. (2010) proposed that MMCs begin with a 
build-up of 5-HT, released from enterochromaffin cells in the 
mucosa of the duodenum during phase I. The released 5-HT 
acts at 5-HT4 receptors within the ENS to increase GI motil-
ity, representing phase II of the MMC. The mechanical activity 
caused by the increased motility is then argued to release more 
5-HT from the enterochromaffin cells, which initiates phase 
III by activating 5-HT4 receptors in the intestine and 5-HT3 
receptors in the stomach. Thus, phase III MMC activity can 
be attenuated by 5-HT3 receptor antagonism when the MMC 
originates in the stomach (Yoshida et al., 1991; Wilmer et al., 
1993; Nakajima et al., 2010) but not clearly in the intestine 
(Davidson et al., 1990). Instead, 5-HT4 receptor antagonism was 
found to inhibit phase II and III MMC activity in the canine 
small intestine, a procedure which was similarly effective in the 
stomach (Nakajima et al., 2010).
The increased contractions also increase the release of motilin 
from endocrine cells in the mucosa to induce or re-enforce   gastric 
phase III MMC activity (Sarna, 1985; Peeters, 1993). Thus, although 
the release of motilin is not prevented by vagotomy (Yoshiya et al., 
1985) or by 5-HT3 receptor antagonism (Yoshida et al., 1991), 
MoveMents oF the hungry stoMach and sMall 
IntestIne
the MIgratIng Motor coMplex
In humans the stomach and small intestine adopt a cyclic pattern 
of motility and secretion during fasting, first noted in association 
with hunger by Boldyreff in St Petersburg, Russia, in 1905, and later 
rediscovered and described as the MMC by Szurszewski (1969) in 
the canine small intestine. MMCs are usually characterized by a 
relatively long period of near-quiescence (phase I), followed by 
a series of short, mostly non-propulsive contractions at irregular 
frequency (phase II) and then a short burst of high-amplitude 
propulsive contractions (phase III; Sarna, 1985; Nieuwenhuijs et al., 
1998; Husebye, 1999). Figure 2 shows an MMC trace taken from an 
8-channel antroduodenal motility recording of a healthy test sub-
ject experiencing a hunger pang. In humans the MMC has a cycle 
time of between 80 and 120 min, during which phase III may last 
around 5–8 min. MMCs can occur during the day or night (when 
phase I occupies a greater time at the expense of phase II) and 
about 60% of phase IIIs begin in the stomach, the rest beginning 
at the ligament of Treitz on the border between the duodenum and 
jejunum (Kellow et al., 1986). MMCs move down the small intestine 
and its characteristic activity front (phase III) terminates in the dis-
tal small intestine. MMC activity is also accompanied by variations 
in splanchnic blood flow, gall-bladder emptying, and gastric and 
pancreatic secretions (Thollander et al., 1996; Nieuwenhuijs et al., 
1998; Husebye, 1999). Ingestion of a meal replaces MMC activity 
with a “feeding pattern” of motility (Sarna, 1985).
It is important to note that considerable species differences exist 
between the characteristics and mechanisms of MMCs. Carnivores 
such as dogs exhibit MMC activity with characteristics similar to 
that of humans (Sarna, 1985). Herbivores such as rabbits and 
rodents (including guinea-pigs, mice, and rats) exhibit different 
MMC patterns and mechanisms. In rabbits the stomach is never 
empty and phase III myoelectric activity can be detected even after 
feeding (Ruckebusch et al., 1985; Guerrero-Lindner et al., 1996). In 
rats, phase III-like MMC activity occurs at a much faster rate than 
in humans and dogs (12–15 min compared with 90–100 min; Argia 
et al., 2007). Further, the clear role of the GI hormone motilin in 
Figure 1 | illustrates the strength of the contractions which begin in the 
middle part of the stomach and which are temporally associated with 
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The reasons why both 5-HT and motilin are involved in regu-
lating the mechanisms which support phase III MMC activity are 
not clear.
assocIatIons between MMcs and the release oF other gI 
horMones
In addition to motilin, other peptides are associated with phase 
III MMC activity. One of the most recently studied is ghrelin, a 
28-amino acid peptide first derived from rat stomach and shown 
to be the natural ligand for the growth hormone (GH) secretagogue 
receptor 1a (Kojima et al., 1999), now renamed as the ghrelin recep-
tor (Davenport et al., 2005). Ghrelin has several actions, among 
which are the ability to release GH and other hormones into the cir-
culation, stimulate appetite, and modulate fat utilization (Williams 
and Cummings, 2005; Huda, et al., 2006; Murphy and Bloom, 2006). 
In humans ghrelin can increase the rate of gastric emptying (e.g., 
Levin et al., 2006) via vagal nerve activation (Asakawa et al., 2001; 
Date et al., 2002; Sakata et al., 2003) and to a lesser extent via 
receptors within the ENS (Dass et al., 2003b; Edholm et al., 2004). 
This prokinetic activity may even induce a premature phase III of 
the MMC (Tack et al., 2006). Nevertheless, the gastric prokinetic 
properties of ghrelin are usually apparent only when high blood 
concentrations of ghrelin are achieved by the use of exogenously 
phase III MMC activity within the stomach can be attenuated by 
motilin antiserum (Lee et al., 1983). Motilin acts by strongly facili-
tating gastric cholinergic motor nerve activity in a short-lasting 
manner (Dass et al., 2003a; Jarvie et al., 2007), consistent with 
its role in mediating the short-lived phase III contractions. The 
released motilin may also activate the vagus nerve. This has been 
demonstrated in conscious dogs, where motilin evoked a transient 
increase in blood plasma concentrations of pancreatic polypeptide 
(Mochiki et al., 1997) and insulin (Suzuki et al., 1998) via vagal 
muscarinic pathways; these effects are consistent with the increase 
in plasma concentrations of both hormones in association with 
phase III gastric MMC activity (Suzuki et al., 1998). Acute vagal 
blockade has also been reported to inhibit the increase in canine 
gastric motility caused by low but not by high doses of motilin 
(Inatomi et al., 1996). Interestingly, induction of a gastric phase 
III-like activity by administration of the motilin receptor agonist 
erythromycin was recently shown to correlate with the sensation 
of hunger (Ang et al., 2008a,b). These observations reinforce the 
suggestion of a role for motilin, released in association with phase 
III of the gastric MMC, to promote hunger either directly (e.g., by 
activating the vagus nerve) or indirectly by promoting the release 
of ghrelin (Zietlow et al., 2010; see below for discussion on the 
role of ghrelin in hunger).
Figure 2 | Propagated phase iii from antrum through jejunum, preceded by phase ii and followed by phase i, of the migrating motor complex of a healthy 
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suppression  of  ghrelin  release  may  be  dependent  on  the  type 
of food (the rank order for suppression was protein > carbohy-
drate > lipid) suggests a finer control than previously appreciated 
(Foster-Schubert and Cummings, 2006). The released ghrelin may 
promote appetite in humans by activation of vagal nerve pathways 
(le Roux et al., 2005) or after release into the blood and transport 
across the blood–brain barrier to act centrally (though active trans-
port systems also exist to remove ghrelin from the brain; Banks 
et al., 2002). Interestingly, the sensitivity of ghrelin receptors may 
be increased during fasting (Scott et al., 2007). Further, an ability of 
ghrelin to inhibit emesis (Rudd et al., 2006), prompts the idea that 
appetite and nausea are opposite ends of the same pathway, so that 
hormones such as ghrelin which increase appetite also reduce nau-
sea, and vice versa (Sanger and Lee, 2008). This activity of ghrelin 
may contribute to the reduction in vomiting observed in patients 
with diabetic gastroparesis following intravenous-administration 
of the ghrelin receptor agonist TZP-101 (Wo et al., 2010). Also, the 
orally active compound TZP-102 is reported to improve symptoms 
within 1 week of treatment initiation with significant reductions in 
symptom scores for nausea, early satiety, excessive fullness, post-
prandial fullness, and the total Gastroparesis Cardinal Symptom 
Index. In addition, improvement of upper and lower abdominal 
pain and discomfort has been noted1 (Presentation by John Wo at 
ACG 2010, October 20, 2010).
Des-acyl-ghrelin
Ghrelin is formed from the non-acylated peptide (des-acyl-ghrelin) 
by a unique post-translational acylation of the third serine residue. 
This modification is mediated by ghrelin O-acyl transferase (GOAT) 
and can be readily reversed by endogenous esterases (Gutierrez 
et al., 2008). GOAT is primarily localized to the stomach and intes-
tine, tissues from which active ghrelin is secreted (Yang et al., 2008). 
Since acylation may be at least partly regulated by nutrient avail-
ability in the gut (Liu et al., 2008), it is becoming clear that the ratio 
of ghrelin to des-acyl-ghrelin may be under physiological and/or 
pathological control. Such control may be important in tissues 
where des-acyl-ghrelin has biological activity.
In blood plasma from healthy volunteers the concentration of 
des-acyl-ghrelin greatly exceeds that of acylated ghrelin (Chen 
et al., 2009) and an ability of this peptide to affect GI function is 
increasingly recognized (Fujimiya et al., 2010). For example, in 
rats, intraperitoneal administration of des-acyl-ghrelin decreased 
food intake in free-feeding rats during the dark, but not the light 
phase of food intake (Chen et al., 2005). However, in another 
example, systemically administered des-acyl-ghrelin did not affect 
appetite in rats and mice but stimulated feeding when adminis-
tered via the intracerebroventricular route, an activity also present 
in ghrelin receptor knock-out mice (Toshinai et al., 2006). These 
data contribute to the hypothesis that des-acyl-ghrelin can act 
via binding sites that are distinct from the ghrelin receptor (Lear 
et al., 2010). Finally, central and systemic administration of des-
acyl-ghrelin may also disrupt fasted but not fed motility in the 
gastric antrum, an activity apparently dependent on activation 
of CRF2 receptors in the brain (after the peptide had crossed the 
administered ghrelin or ghrelin receptor agonists (Camilleri et al., 
2009). Further, there have been no studies demonstrating a cyclical 
release of ghrelin which coincides with the phases of the MMC. 
Instead, ghrelin levels display a diurnal rhythm in humans, with 
a peak at night during fasting, and lowest concentrations in the 
morning after breakfast (Cummings et al., 2001). It is, therefore, 
unlikely that ghrelin is involved in the physiological regulation of 
MMCs in man.
It has been reported that increases in blood concentrations of 
somatostatin occur in association with phase III MMC activity origi-
nating in the stomach and duodenum (Peeters et al., 1983; Chung 
et al., 1995; Tomita, 2009) although this was not found in two other 
studies where duodenal MMCs were recorded (Näslund et al., 1998; 
Medhus et al., 1999); nevertheless, increased duodenal intralumi-
nal concentrations were observed (Näslund et al., 1998). The exact 
role of the released somatostatin is not clear, since intravenous-
administration of somatostatin or the somatostatin SST2 receptor 
agonist octreotide may abolish all activity within the stomach, delay 
small intestinal transit and inhibit intestinal phase II activity while 
initiating phase III-like activity (Peeters et al., 1983; Von der Ohe 
et al., 1995). In addition to somatostatin, peak intraduodenal levels 
of VIP and substance P have also been associated with human duo-
denal phase III activity (Näslund et al., 1998), suggesting an ability 
of certain neuropeptides to modulate GI functions during this phase 
of the MMC, after diffusion into local neurocircuits. Increases in 
blood concentrations of xenin (found in specific endocrine cells of 
duodenal mucosa) have also been found in association with phase 
III MMC activity and when given IV initiate phase III-like activity 
in intestine (Feurle et al., 2001). Finally, relationships between MMC 
activity and blood plasma concentrations of other gut hormones 
such as gastrin, glucagon, gastric inhibitory polypeptide (Rees et al., 
1982), vasoactive intestinal peptide, or substance P, have not been 
found (Näslund et al., 1998).
gI horMones, hunger, and appetIte
Fasting decreases the availability of hormones such as leptin and 
glucagon-like peptide-1, which are released from the gut after eat-
ing meals to reduce appetite and help control the flow of nutri-
ents down the GI tract (Näslund and Hellström, 2007). However 
the availability of other GI hormones is increased. In addition to 
motilin these include ghrelin and orexin, which are not released 
in close association with MMC activity, but can influence hunger 
and metabolism.
products oF the preprogene ghrelIn gene
This extraordinary gene generates three different peptides, des-
acyl-ghrelin, ghrelin, and obestatin, which may each have their 
own functions but which also interact to regulate the functions of 
ghrelin. Each is described separately.
Ghrelin
The release of this hormone from endocrine cells within the stom-
ach (where the largest amounts are found) increases plasma ghrelin 
concentrations in humans during fasting. The fact that plasma 
concentrations rise just before mealtimes and drop after eating, 
prompted Cummings et al. (2001) to suggest a role for ghrelin 
in meal initiation. Later studies showing that the magnitude of 
1http://www.news-medical.net/news/20100629/Tranzyme-reports-positive-results-
from-TZP-102-Phase-2-study-in-diabetic-patients-with-gastroparesis.aspxwww.frontiersin.org  February 2011  | Volume 1  | Article 145  |  5
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increased gastric emptying (Moechars et al., 2006) and a changed 
glucose-dependent insulin secretion (Tremblay et al., 2009). Do 
these observations suggest that the cognate ligand for GPR39 will 
have profound effects on GI functions? Clues may be provided 
by the suggestion that GPR39 is the receptor which mediates the 
ability of free zinc ions (Zn2+) to affect cell functions (Egerød et al., 
2007). GPR39 receptors are found throughout the GI tract (Egerød 
et al., 2007; Yamamoto et al., 2009) raising the possibility that these 
receptors mediate the ability of Zn2+ to modulate colonocyte func-
tions such as proliferation, ion transport, and hormone transport, 
reduce epithelial erosion and inhibit diarrhea (Azriel-Tamir et al., 
2004; Hershfinkel et al., 2007; Sharir et al., 2010). A role for Zn2+-
sensitive receptors in upper GI functions is not clear but now needs 
to be investigated.
orexIn
Plasma  concentrations  of  orexin  also  increase  during  fasting 
(Komaki et al., 2001). This hormone, present as orexin A and 
B in the myenteric plexus and endocrine cells of the human GI 
tract (and pancreas; Nakabayashi et al., 2003) has been reported 
to depolarize enteric neurons and facilitate gastric nitrergic activ-
ity in rodents (Katayama et al., 2005; Baccari et al., 2009), inhibit 
rat small intestinal MMC activity, stimulate rat gastric emptying 
and increase acid secretion (Näslund et al., 2002; Bülbül et al., 
2010). However, in healthy human volunteers, infusion of orexin 
caused only a small inhibition of gastric emptying and failed to 
affect appetite (Ehrström et al., 2005), suggesting that the release 
of orexin from endocrine cells of the gut during fasting may play 
only a minor role in the control of human gastric emptying during 
hunger. Instead, the decrease in plasma concentrations of leptin and 
increase in insulin suggest a possible role in metabolic regulation 
(Ehrström et al., 2005).
dysregulatIon oF the hungry huMan stoMach
gastroIntestInal MotIlIty
Disorders associated with disrupted MMC activity are not com-
mon, although clearly MMCs are absent during the paralytic ileus 
which follows abdominal and other types of surgery. MMCs reoc-
cur in the proximal small intestine within 3 h after the surgery but 
initially with a quicker cycle time and reduced Phase II activity 
(Benson et al., 1994; Husebye, 1999). Interesting, patients under-
going gastrectomy for gastric cancer who then had Roux-en-Y 
reconstruction (the stomach is removed and to achieve continu-
ity to the intestine the proximal jejunum is divided and the aboral 
jejunum anastomosed to the esophagus – the divided oral part of 
the jejunum is reconnected to the jejunum distal to the esophageal 
anastomosis so bile and pancreatic secretions can be directed into 
the jejunum and the shape of a Y is created), could be divided into 
those with intestinal MMC activity and those without (Tomita 
et al., 2003). Compared to the latter, patients with phase III MMC 
activity tended to have more appetite and greater food intake, as 
well as fewer symptoms associated with dumping, reflux, nausea or 
lower bowel symptoms. These observations show the importance 
of the MMC activity in eliciting hunger sensations.
Vantrappen et al. (1977) hypothesized that a dysfunctional 
MMC would lead to bacterial overgrowth within the upper gut, 
in an environment favored by accumulation of food remnants, 
blood–brain barrier) but curiously, not on vagal nerve activity 
(Chen et al., 2005). Together, these data indicate a need to further 
explore the GI roles of des-acyl-ghrelin.
Obestatin
This peptide was identified through sequence analysis of the ghrelin-
precursor gene, proghrelin (Zhang et al., 2005). Initially, obestatin 
was thought to be the endogenous ligand for the orphan G protein-
coupled receptor GPR39, and when systemically administered was 
shown to suppress feeding and weight gain in mice in a time- and 
dose-dependent manner, as well as reduce rat gastric emptying 
(Zhang et al., 2005). Unfortunately the proposal that obestatin rep-
resented the endogenous ligand for GPR39 is no longer accepted 
(Wigglesworth et al., 2006; Holst et al., 2007; Zhang et al., 2007). 
Nevertheless, the ability of obestatin to inhibit food intake has been 
replicated (Zhang et al., 2007) and confirmed or partly confirmed 
(Bresciani et al., 2006; Sibilia et al., 2006; Lagaud et al., 2007; Chen 
et al., 2009), although not when administered centrally (albeit using 
a different protocol; Seoane et al., 2006). However, it is worth noting 
that although obestatin was shown to have a considerable effect on 
food intake, there was no actual reduction in body weight but rather 
a slower weight gain; changes in fat mass were not measured (Zhang 
et al., 2005). Another study suggests that obestatin may increase 
thirst (Samson et al., 2007). Finally, serum leptin levels were not 
affected by either ghrelin (Zhang et al., 2005; Falkén et al., 2010) 
or obestatin (Zhang et al., 2005), suggesting that both these effects 
were outside of adipose tissue and most likely confined to the GI 
tract (Nogueiras and Tschöp, 2005).
Several studies have failed to demonstrate significant effects of 
obestatin on GI motility when using in vitro models, when meas-
uring MMC activity or gastric emptying of a non-nutrient meal 
(Gourcerol et al., 2006; Bassil et al., 2007; De Smet et al., 2007). 
Ataka et al. (2008) confirmed these observations but then showed 
that the gastro-duodenal motility of rats after eating standard chow 
was inhibited 30–90 min after intravenous-administration of obes-
tatin. This inhibitory action appeared to be dependent on CRF1 
and CRF2 receptor activity within the brain, and for the duodenum 
but not the antrum, was also prevented by capsaicin pretreatment. 
From these and other data, the authors suggested that obestatin acts 
centrally (after crossing the blood–brain barrier) and at the vagus, 
to inhibit rat upper GI motility, but only after feeding (Ataka et al., 
2008; Fujimiya et al., 2010).
The studies with obestatin and GPR39 raise important ques-
tions. Firstly, since obestatin has undoubted biological activity and 
since immunoreactivity for obestatin has been detected in the rat 
gastric mucosa and in myenteric plexus (Dun et al., 2006), what 
is the role of this source of obestatin and what receptor does it act 
on? One possibility is suggested by the fact that obestatin appears 
to act in a manner which is opposite to that of ghrelin – reducing 
appetite and gastric emptying after meals, and antagonizing certain 
functions of ghrelin (Zhang et al., 2005; Bassil et al., 2007; Fujimiya 
et al., 2010; Kumar et al., 2010). Such activity points toward a role in 
the mechanisms of nausea, contrasting to the anti-emetic activity of 
ghrelin (Rudd et al., 2006). Another question is created by reports 
that GPR39 is upregulated in rat adipose tissue during fasting 
(Egerød et al., 2007) and that mice lacking GPR39 appear to have 
normal food intake and body weight gain (Tremblay et al., 2007) but Frontiers in Pharmacology  | Gastrointestinal Pharmacology    February 2011  | Volume 1  | Article 145  |  6
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translatIon to drugs
Increased understanding of the different roles played by hormones 
released from the gut during fasting has provided new opportuni-
ties for the development of new drugs. To date, motilin and ghrelin 
are the hormones which have received the most attention.
MotIlIn receptor antagonIsts
Recent progress in identification of selective antagonists has been 
described by Westaway and Sanger (2009). Oral dosing of the 
motilin receptor antagonist MA-2029 to rabbits reduced motilin-
induced colonic contractions (Sudo et al., 2008). MA-2029 also 
reduced abdominal muscle contractions induced by adminis-
tration of motilin in combination with colorectal distension, 
indicating a reduction in the visceral pain experienced by these 
animals that had been exacerbated by motilin (Sudo et al., 2008). 
Similarly, MA-2029 inhibited motilin-induced increases in gas-
tric fundus tone, GI transit, and diarrhea in conscious dogs 
without effects on basal GI tone or motility (Ozaki et al., 2009). 
However, although these experiments demonstrate the pharma-
codynamic characteristics of MA-2029 (i.e., they establish that 
the antagonist can block the effects of exogenously administered 
motilin in vivo) they do not demonstrate a pathophysiological 
role for motilin. Evidence for such a role is provided by the mac-
rocyclic peptidomimetic and motilin receptor antagonist TZP-
201, which reduced the incidence of diarrhea in a dog model of 
chemotherapy-induced diarrhea providing a superior level of 
efficacy compared to loperamide and octreotide (Thomas et al., 
2007). If confirmed, these data represent an important break-
through in establishing a potential therapeutic use for motilin 
receptor antagonists. TZP-201 was also shown to antagonize 
motilin-induced contractile activity of the colon of the musk 
shrew (Venkova et al., 2009a). Although this is again a simple 
pharmacodynamic study, it is nevertheless, an important obser-
vation because these animals represent a small laboratory animal 
that actually possesses a functional motilin receptor.
MotIlIn receptor agonIsts
In addition to its antibiotic use, erythromycin is used clinically 
as a gastric prokinetic agent. The latter has been described for 
a number of different disorders associated with delayed gastric 
emptying (Sanger, 2008), including patients in critical care receiv-
ing enteral feeding (given via a naso-gastric tube; enhanced gastric 
emptying improves delivery of nutrients, reduces the time needed 
for intubation, and the incidence of complications such as pulmo-
nary aspiration or infection, improving survival), diabetic patients 
needing better control of blood glucose, and patients with diabetic- 
or non-diabetic gastroparesis where improved gastric emptying 
can reduce symptoms. Nevertheless, the ability of erythromycin 
to inhibit the cytochrome P450 enzyme CYP3A4 and cause drug–
drug interactions (Zhou et al., 2004), together with the use of 
erythromycin as a gastric prokinetic agent in an age when antibi-
otic resistance continues to rise, highlights the pressing need for 
alternative medication. The use of erythromycin also highlights 
the extraordinary lack of safe and effective gastroprokinetic drugs 
(Sanger and Alpers, 2008). An improved, selective motilin recep-
tor agonist would, therefore, have potential use in each of the 
conditions described above. A role for motilin receptor agonists in 
desquamated cells, and secretions. Such patients were detected 
using a 14CO2 bile acid breath test and treated successfully with 
antibiotic drugs. The number of patients studied were, how-
ever, too small to speculate on the causes of the dysfunctional 
MMC.
Phase III-like activity persists in mechanically ventilated patients 
with critical illness, following perfusion of the small intestine with 
liquid nutrients (Chapman et al., 2005). Plasma motilin concentra-
tions may be increased during such infusions, rather than decreased 
as in healthy volunteers (Nguyen et al., 2010). The reasons for these 
differences are not clear.
Migrating motor complex activity has often been studied in 
patients with functional bowel disorders, especially irritable bowel 
syndrome. Small variations have been observed, critically discussed 
by Husebye (1999). The role of any changes in the etiology of the 
disorders is, however, far from clear, being most likely caused by the 
disorder itself. Perhaps the most interesting are a group of patients 
with an idiopathic delay in gastric emptying where MMC activity 
was reduced or absent (Labò et al., 1990).
Finally, although not a disorder of hunger itself, gastric phase 
III MMC activity may lead to increased gastro-esophageal reflux 
during the night (Gill et al., 1987). This activity, observed in 
healthy  individuals,  has  clear  consequences  for  patients  with 
hiatus hernia.
horMonal status
There are physiological and pathological conditions characterized 
by high circulating ghrelin levels. These include starvation, ano-
rexia nervosa (Otto et al., 2001), bulimia (Tanaka et al., 2002), and 
cachexia (Nagaya et al., 2001), in which ghrelin values are doubled, 
compared with normal controls. Binge eating has been associated 
with a dysfunction in the ghrelin signaling system and with a reduc-
tion in post-prandial satiety cues arising from an increase in gastric 
capacity (Hellström et al., 2004).
In patients with anorexia nervosa, plasma concentrations of 
ghrelin are paradoxically higher (Nakai et al., 2003) but return 
to normal as patients increase in weight; it has been demon-
strated that there is a specific reduction in the GH response to 
ghrelin, despite the hyper-responsiveness to administration of 
GH releasing hormone. The impaired GH response to ghrelin 
could  reflect  desensitization  of  the  ghrelin  receptor  induced 
by chronic elevation of ghrelin levels in this pathological state 
(Broglio et al., 2004). Interestingly there is one report of a patient 
with a ghrelin-producing neuroendocrine tumor who had cir-
culating plasma concentrations of ghrelin of 12000 pM. There 
is no report regarding hunger sensations in this patient but she 
was obese (BMI 29.9 kg/m2) and had type 2 diabetes mellitus 
(Corbetta et al., 2003).
Clinical  conditions  associated  with  changes  in  blood  con-
centrations of des-acyl-ghrelin and obestatin are as yet, unclear. 
Nevertheless, important biological functions are suggested by close 
links between ghrelin and obestatin (both are co-produced and 
their ligand and receptor sequences are highly conserved through-
out mammalian evolution, along with the functions; Kaiya et al., 
2008) and ghrelin and des-acyl-ghrelin (Kumar et al., 2010). The 
effects of these peptides now need to be studied in man, especially 
in patients with obesity and/or nausea.www.frontiersin.org  February 2011  | Volume 1  | Article 145  |  7
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The most advanced is mitemcinal, the remaining macrolide still 
in clinical development (Takanashi and Cynshi, 2009), which has 
shown some ability to improve symptoms in a subset of patients 
with diabetic gastroparesis, good glycemic control and a body mass 
index of <35 kg/m2 (McCallum et al., 2007). Interestingly, attempts 
to profile the desensitization liability of mitemcinal in vitro illus-
trate the fact that several assays commonly used to examine the 
functions of motilin in vitro, actually lack translational value. For 
example, the abilities of mitemcinal and other motilin receptor 
agonists to cause contraction of rabbit isolated duodenal mus-
cle were reported to undergo rapid tachyphylaxis (Carreras et al., 
2004). A desensitization liability was also noted using CHO cells 
expressing the human motilin receptor (Takanashi and Cynshi, 
2009). By contrast, in human volunteers, the ability of mitemcinal 
to increase gastric emptying was maintained over a 28-day repeat-
dose schedule (McCallum et al., 2007). This anomaly led to the 
suggestion (Sanger, 2008; Westaway and Sanger, 2009) that a more 
meaningful in vitro assay was to examine the abilities of motilin 
receptor agonists to facilitate on-going gastric neuronal activity, 
argued to represent a more physiological model of gastric motility. 
Using this model, GSK962040, the most advanced non-motilide 
small molecule motilin receptor agonist, has been shown to act in 
a manner similar to that of erythromycin, facilitating cholinergic 
contractile activity in rabbit (Sanger et al., 2009) and human (Broad 
et al., 2010) isolated stomach, in a prolonged manner. GSK962040 is 
currently being evaluated in healthy volunteers, where both singly 
administered (Dukes et al., 2009) repeated doses (Dukes et al., 2010) 
accelerated gastric emptying in a maintained manner.
Finally, RQ-00201894 has been described as a non-motilide, 
small molecule, potent, and selective motilin receptor agonist. 
However, its structure is currently unknown. This molecule is 
said to increase gastric emptying in dogs and monkeys, as well 
as induce gastric Phase III-like activity in dogs (Takahashi et al., 
2010).
ghrelIn receptor antagonIsts
The  use  of  ghrelin-specific  antibodies,  immunization  against 
endogenous ghrelin, “RNA Spiegelmers” such as l-NOX-B11 (oli-
gonucleotides made stable by placing unnatural l-enantiomers of 
ribose in the sugar–phosphate backbone) and even a vaccine has 
shown that in adult animals (usually rodents), inhibition of on-
going ghrelin function can reduce food intake and body weight 
(Foster-Schubert and Cummings, 2006; Zorrilla et al., 2006; Becskei 
et al., 2008; Depoortere, 2009). These data indicate the potential 
value of a small molecule ghrelin receptor antagonist (Moulin et al., 
2007). Several have been shown to be active against the receptor 
that is naturally expressed (e.g., in rat isolated pituitary cells) and 
some have demonstrated an ability to reduce food intake and body 
weight in rodents as well as improve glucose tolerance (e.g., Esler 
et al., 2007, who used mice for the feeding experiments and rats for 
the glucose tolerance test). However, as yet, none have progressed 
into the clinic.
ghrelIn receptor agonIsts
The multiple activities of ghrelin make this an interesting drug 
target. Its ability to increase appetite suggests a role in treatment 
of cachectic patients (Ashitani et al., 2009), as exemplified by 
reducing post-operative ileus is also suggested by the involvement 
of motilin in phase III of the gastric MMC, the return of which is 
used a marker of recovery.
At first, the clinical efficacy of erythromycin as a prokinetic 
agent may seem surprising in view of the short-lived action of 
motilin itself; indeed tolerance to repeat-dose erythromycin has 
been observed (Richards et al., 1993; see below). To understand 
these apparently conflicting observations, Dass et al. (2003a) and 
Jarvie et al. (2007) conducted a series of experiments with rabbit 
isolated stomach, in which the pharmacology of motilin receptor 
agonists were examined for their abilities to facilitate cholinergi-
cally mediated contractions evoked by electrical field stimulation. 
This model is argued to provide a more physiological representa-
tion of their abilities to facilitate on-going gastric emptying (in 
which the ENS plays a key role), than alternative models which 
simply investigate their effects on resting muscle tension. Using 
this technique, low concentrations of motilin were found to greatly 
facilitate cholinergic activity but in a short-lived manner, consistent 
with a role for motilin in the short-lasting gastric phase III MMC 
activity. However, low concentrations of erythromycin induced 
long-lasting increases in cholinergic activity which did not rapidly 
fade; higher concentrations of erythromycin evoked greater but 
shorter-lived responses and also increased muscle tension. Similar 
observations have now been made using human isolated stomach 
in which contractions were evoked by electrical field stimulation 
(Broad et al., 2010). Together, these observations are consistent with 
the finding that low doses of erythromycin (50–100 mg 3× daily 
and at bedtime) reduced symptoms in patients with gastropare-
sis (Dhir and Richter, 2004) whereas higher doses may tolerate 
with repeat dosing (250–400 mg 4× daily; Richards et al., 1993). 
Similarly, symptoms associated with gastroparesis may be improved 
by repeated   intravenous-administration of erythromycin, provided 
the dose was titrated to achieve efficacy and tolerance in each patient 
(Dibaise and Quigley, 1999). Further, in human volunteers, a low 
dose of erythromycin (40 mg) evoked an increase in gastric pro-
pulsive activity which could be prevented by atropine (Coulie et al., 
1998), whereas a higher dose (200 mg) evoked atropine-resistant, 
non-propulsive contractions (Coulie et al., 1998) and an increase 
in meal-induced satiety (Cuomo et al., 2006). Thus, low doses of 
erythromycin appear to behave in a manner which differs from 
that of motilin or high doses of erythromycin. The explanation is 
not clear and speculation centers on possible different binding sites 
for the peptide and non-peptide structures (Matsuura et al., 2006). 
The isolated tissue results are also consistent with observations that 
repeat dosing with low doses of erythromycin may increase gastric 
emptying whereas higher doses can induce nausea and stomach 
cramping (Boivin et al., 2003).
The experiments described above argue that it is possible to 
identify alternative molecules which mimic the actions of erythro-
mycin but in a more selective manner, without the antibiotic activity 
or ability to inhibit P450 activity. Until recently, these molecules 
were based on the complex macrolide structure of erythromycin, 
where small changes in structure removed antibiotic activity but 
additional changes to optimize the “drug-like” properties of the 
molecule in an iterative manner are extremely difficult; to date, 
most have not progressed far in the clinic (Westaway and Sanger, 
2009). Table 1 lists the motilin receptor agonists recently described. Frontiers in Pharmacology  | Gastrointestinal Pharmacology    February 2011  | Volume 1  | Article 145  |  8
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may be dependent on vagal nerve activity (Page et al., 2007; Sanger, 
2008). Success in the development of such an agent may lie in 
selecting a patient group where the new drug is only required on 
an acute basis (e.g., post-operative ileus), as a potential difficulty 
with a long-term exposure is the widespread ability of ghrelin to 
increase endocrine release (Leite-Moreira and Soares, 2007). The 
need for this caution is exemplified by a study which shows that 
constant intravenous infusion of ghrelin may provoke a fall in insu-
lin sensitivity (Vestergaard et al., 2007).
Currently the most advanced is TZP-101 (ulimorelin), an intrave-
nously administered macrocyclic peptidomimetic (Fraser et al., 2005) 
reported to improve GI recovery in patients with post-operative ileus 
after abdominal surgery (Popescu et al., 2009) and improve symp-
toms (loss of appetite, vomiting, post-prandial fullness) 4 days after 
treatment in patients with diabetic gastroparesis (Wo et al., 2010). 
A second molecule, TZP-102, is said to be orally available and have 
gastric prokinetic properties2, but details have not been published 
studies in cancer patients with impaired appetite where ghrelin 
increased energy intake and meal appreciation during a buffet 
meal (Neary et al., 2004). The ability of ghrelin to increase gastric 
emptying also suggests a role in treatment of disorders associated 
with delayed gastric emptying, as exemplified by animal models 
of post-operative gastric ileus (Trudel et al., 2003) or septic ileus 
(De Winter et al., 2004). Finally, an anti-emetic activity of ghrelin 
(Rudd et al., 2006), combined with the ability to increase appetite 
and gastric emptying suggests a potential to treat more complex 
conditions such as dyspepsia, as exemplified in an animal model of 
this condition (Liu et al., 2006) and as suggested by raised plasma 
ghrelin levels in patients with functional dyspepsia (Nishizawa 
et al., 2006).
Table 1 lists the ghrelin receptor agonists being evaluated for a 
GI disorder. In general, these compounds were first characterized 
using recombinant receptors, followed by studies in vivo, where 
their ability to increase gastric emptying and stimulate feeding 
Table 1 | Motilin and ghrelin receptor agonists under development for the treatment of gi disorders.
Compound  Status  Structure
MoTilin reCePTor agoniSTS
Mitemcinal (GM-611)  Phase II; diabetic gastroparesis
 
RQ-00201894  Preclinical  Small molecule, non-macrolide; structure 
    not yet disclosed
GSK962040  Phase I
 
ghrelin reCePTor agoniSTS
Ulimorelin (TZP-101)  Entering phase III as IV formulation for GI dysmotility 
  conditions in acute care
TZP-102  Phase II for gastroparesis  Orally active macrocyclic peptidomimetic
Ipamorelin  Phase II; for opioid-induced bowel dysfunction 
EX-1314 (previously known as  Preclinical  dimethyl glycyl-O-benzyl-serine 
BMS-604992)
ST-1141  Phase I; for opioid-induced bowel dysfunction  Structure not yet disclosedwww.frontiersin.org  February 2011  | Volume 1  | Article 145  |  9
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